(Q419939)

doxazosin (English)

3 October 2016

C₂₃H₂₅N₅O₅

1 reference

doxazosin (English)

19 November 2016

COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC

1 reference

doxazosin (English)

19 November 2016

4 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=C02CA04

1 reference

14 February 2018

World Health Organisation international non-proprietary name

doxazosin (English)

1 reference

doxazosin (English)

medical condition treated

3 October 2016

2 references

13 December 2016

https://www.ncbi.nlm.nih.gov/pubmed/11505534

prostatic hypertrophy

2 references

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

arterial hypertension

2 references

13 December 2016

Drug Indications Extracted from FAERS

Food and Drug Administration

2 October 2018

prostatic hypertrophy

start time

2 November 1990

approved by

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/NW1291F1W8

https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019668s021lbl.pdf

arterial hypertension

start time

2 November 1990

approved by

Food and Drug Administration

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/NW1291F1W8

https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019668s021lbl.pdf

significant drug interaction

tadalafil

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

avanafil

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-metoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vardenafil

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

nadolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atenolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nebivolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sildenafil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acebutolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

betaxolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bisoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pindolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

carvedilol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

propranolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

labetalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celiprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levobunolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Adrenoceptor alpha 1A

subject has role

antagonist

1 reference

17 August 2016

Adrenoceptor alpha 1B

subject has role

antagonist

1 reference

17 August 2016

Adrenoceptor alpha 1D

subject has role

antagonist

1 reference

LiverTox likelihood score

17 August 2016

LiverTox toxicity likelihood category E*

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Doxazosin

8 January 2018

1 reference

5 March 2018

antihypertensive drug

1 reference

Medical Subject Headings

MeSH descriptor ID

D017292

adrenergic alpha-1 receptor antagonists

15 March 2018

1 reference

InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)

Medical Subject Headings

15 March 2018

Doxazosin

0 references

Identifiers

InChI

1 reference

doxazosin (English)

19 November 2016

2 references

doxazosin (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

74191-85-8

2 references

doxazosin (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=74191-85-8

9 April 2021

1 reference

Doxazosin (English)

19 November 2016

2 references

doxazosin (English)

19 November 2016

Reaxys registry number

731849

1 reference

doxazosin (English)

3 October 2016

mapping relation type

2 references

DOXAZOSIN (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)

1 reference

DOXAZOSIN (English)

19 November 2016

2 references

inferred from InChIKey

splash10-0udi-0002900000-3097c8a3403b52610918

1 reference

MassBank accession ID

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

splash10-0006-0079100000-06d36a9b7afe6cf0c6e9

0 references

splash10-000t-1091000000-cbd9b2106818ef5fd2ba

0 references

splash10-001i-1190000000-a1c84b0c3657d8000e35

0 references

splash10-001i-1390000000-e802cb93ca8d6934ee96

0 references

splash10-0udi-0010900000-9601aa919c95799ec009

0 references

splash10-0kei-0981100000-a9ee3121ba6832366f8e

0 references

splash10-0a4i-0970000000-5261f1bc60ceee4364de

0 references

splash10-0a4i-0950000000-f649236044e4e2a5de38

0 references

splash10-0a4i-1920000000-86655cc3bb892d757068

0 references

splash10-0a4i-1900000000-88bca2ddf2930fa0c468

0 references

DSSTox substance ID

DTXSID7022964

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.128.642

27 December 2018

ECHA Substance Infocard ID

2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine (English)

quotation

CAS no.: 74191-85-8 (English)

100.128.642

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.128.642

27 December 2018

2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine (English)

quotation

CAS no.: 74191-85-8 (English)

1 reference

Doxazosin (English)

publication date

17 November 2015

1 reference

doxazosin (English)

19 November 2016

Doxazosin

0 references

MeSH tree code

D03.633.100.786.750.200

0 references

RxNorm ID

49276

1 reference

doxazosin (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0014728

2 references

based on heuristic

inferred from InChIKey

2 references

doxazosin (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

doxazosin (English)

19 November 2016

0 references

1 reference

1 reference

doxazosin (English)

3 October 2016

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

doxazosin (English)

3 October 2016

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

Römpp online ID

RD-04-02490

1 reference

imported from Wikimedia project

1 reference

doxazosin (English)

19 November 2016

0 references

WordNet 3.1 Synset ID

03234359-n

1 reference